State Street Corp Arcus Biosciences, Inc. Transaction History

State Street Corp

  • $2.41 Trillion
  • Q3 2024

A detailed history of State Street Corp transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, State Street Corp holds 3,011,174 shares of RCUS stock, worth $42.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,011,174
Previous 3,055,056 1.44%
Holding current value
$42.8 Million
Previous $46.5 Million 1.05%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$13.69 - $18.01 $600,744 - $790,314
-43,882 Reduced 1.44%
3,011,174 $46 Million
Q2 2024

Aug 14, 2024
SELL
$14.59 - $18.48 $27 Million - $34.2 Million
-1,849,457 Reduced 37.71%
3,055,056 $46.5 Million
Q1 2024

May 15, 2024
BUY
$14.83 - $20.18 $9.86 Million - $13.4 Million
664,936 Added 15.68%
4,904,513 $92.6 Million
Q4 2023

Feb 14, 2024
BUY
$13.43 - $19.63 $531,196 - $776,425
39,553 Added 0.94%
4,239,577 $81 Million
Q3 2023

Nov 14, 2023
SELL
$17.62 - $23.54 $2.51 Million - $3.35 Million
-142,224 Reduced 3.28%
4,200,024 $75.4 Million
Q2 2023

Aug 14, 2023
SELL
$16.97 - $22.03 $19.6 Million - $25.4 Million
-1,154,005 Reduced 21.0%
4,342,248 $88.2 Million
Q1 2023

May 15, 2023
BUY
$15.96 - $23.15 $31.2 Million - $45.2 Million
1,951,970 Added 55.07%
5,496,253 $100 Million
Q4 2022

Feb 14, 2023
SELL
$19.7 - $35.71 $11.8 Million - $21.3 Million
-597,777 Reduced 14.43%
3,544,283 $73.3 Million
Q3 2022

Nov 15, 2022
SELL
$23.23 - $30.07 $6.82 Million - $8.83 Million
-293,789 Reduced 6.62%
4,142,060 $108 Million
Q2 2022

Aug 15, 2022
BUY
$17.23 - $37.73 $29 Million - $63.6 Million
1,685,930 Added 61.31%
4,435,849 $112 Million
Q1 2022

May 16, 2022
BUY
$28.92 - $41.83 $16.1 Million - $23.3 Million
557,988 Added 25.46%
2,749,919 $86.8 Million
Q4 2021

Feb 14, 2022
SELL
$31.38 - $48.47 $4.38 Million - $6.77 Million
-139,699 Reduced 5.99%
2,191,931 $88.7 Million
Q3 2021

Nov 15, 2021
SELL
$26.93 - $37.68 $9.54 Million - $13.3 Million
-354,071 Reduced 13.18%
2,331,630 $81.3 Million
Q2 2021

Aug 16, 2021
BUY
$22.75 - $35.77 $11.8 Million - $18.6 Million
520,307 Added 24.03%
2,685,701 $73.7 Million
Q1 2021

May 17, 2021
BUY
$26.16 - $41.39 $8.96 Million - $14.2 Million
342,539 Added 18.79%
2,165,394 $60.8 Million
Q4 2020

Feb 16, 2021
SELL
$17.0 - $32.36 $11.8 Million - $22.5 Million
-695,613 Reduced 27.62%
1,822,855 $47.3 Million
Q3 2020

Nov 10, 2020
BUY
$17.14 - $25.47 $16 Million - $23.7 Million
930,969 Added 58.64%
2,518,468 $43.2 Million
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $13.2 Million - $34.5 Million
943,962 Added 146.68%
1,587,499 $39.3 Million
Q1 2020

May 11, 2020
BUY
$8.78 - $19.28 $5.65 Million - $12.4 Million
643,537 New
643,537 $8.93 Million

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
51.5M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.02B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email